Limited Edition Myeloma Action Month Grey Unisex T-shirt. Front of the shirt reads I AM RESILIENT, and back of the shirt has large Myeloma Action Month logo. Available for a limited time only.

IMF I AM RESILIENT Pin. The high-quality Pin is made from metal and is a perfect to add to your I AM RESILIENT t-shirt, lapel, or Myeloma Warrior hat!

High-quality Unisex Crewneck Sweatshirt. Front of shirt has small IMF Logo, and back of shirt has large Myeloma Warrior Logo. Back of shirt Myeloma Warrior Logo is available in either "Heart" or "Shield". See photos to choose your favorite, or get both!

High-quality Unisex Crewneck Sweatshirt. Front of shirt has small IMF Logo, and back of shirt has large Myeloma Warrior Logo. Back of shirt Myeloma Warrior Logo is available in either "Heart" or "Shield". See photos to choose your favorite, or get both!

High-quality Unisex Hooded Long-Sleeved *Lightweight Sweatshirt. Zippered front with small IMF Logo, and back has large Myeloma Warrior Logo. Back of shirt Myeloma Warrior Logo is available in either "Heart" or "Shield". See photos to choose your favorite, or get both!

High-quality Unisex Hooded Long-Sleeved *Lightweight Sweatshirt. Zippered front with small IMF Logo, and back has large Myeloma Warrior Logo. Back of shirt Myeloma Warrior Logo is available in either "Heart" or "Shield". See photos to choose your favorite, or get both!

High-quality Mens Crewneck T-Shirt. Front of shirt has small IMF Logo, and back of shirt has large Myeloma Warrior Logo. Back of shirt Myeloma Warrior Logo is available in either "Heart" or "Shield". See photos to choose your favorite, or get both!

High-quality Womens V-Neck T-Shirt. Front of shirt has small IMF Logo, and back of shirt has large Myeloma Warrior Logo. Back of shirt Myeloma Warrior Logo is available in either "Heart" or "Shield". See photos to choose your favorite, or get both!

High-quality adjustable baseball cap. Front of cap has embroidered Myeloma Warrior "Heart" Logo. This hat is one of our teams favorite items.

(10 Pack) IMF Myeloma Warrior Wrist Band. Made from Silicone and is in Myeloma Red and debossed with #MyelomaWarrior myeloma.org one size fits all.

IMF Myeloma Warrior Heart Pin. High-quality Myeloma Warrior Pin is made from metal and is a perfect to add to your t-shirt, lapel, or Myeloma Warrior Hat!

The IMF Info Pack provides comprehensive information on treatment options and disease management. Available free of charge, the Info Pack includes The IMF Patient Handbook, as well as many of the important Understanding Series booklets. Click on the thumbnail to the left to see a complete list of the publications included in the Info Pack.

Prepared by Dr. Brian G.M. Durie, the IMF's Concise Review of the Disease and Treatment Options provides an in-depth overview of myeloma, with a discussion of the epidemiology, pathophysiology, clinical features, treatment options, and new and emerging treatments. This information is helpful to health professionals and patients alike.

The Patient Handbook provides a basic understanding of myeloma to allow patients to make informed decisions about treatment choices.

Clinical trials are research studies of new treatments that involve patients. Whether or not to participate in a clinical trial is one of the critical decisions you and your oncologist may have to make at some point in the cancer care continuum.

Darzalex® (daratumumab) is a laboratory-made monoclonal antibody that targets a specific single protein on the surface of myeloma cells.

After reading this booklet, you should know what Dexamethasone is, how it works, possible side effects, and more.

Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication, Understanding the Immune System in myeloma.

Farydak® (panobinostat) is the first histone deacetylase (HDAC) inhibitor approved for use in treating myeloma. Farydak® is taken in capsule form in combination with Velcade® (bortezomib) and dexamethasone by patients who have already been treated with Velcade® and an immunomodulatory drug.

Myeloma patients may experience fatigue caused by the disease, by treatment, and by the understandable anxiety and/or depression that affects many. This booklet contains a thorough examination of coping strategies and causes of myeloma fatigue, as well as suggestions for discussing fatigue with your doctor.

This publication discusses the use of Freelite (serum free light chain assay) and Hevylite (serum heavy/light chain assay) tests for monitoring myeloma.

High-dose therapy with stem cell rescue, or "stem cell transplant", is an important treatment option for eligible patients with multiple myeloma.

This booklet discusses Kyprolis® (carfilzomib), the results of clinical trials with Kyprolis®, how and when it is administered, its possible side effects, and how to manage them.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are not active disease states, but both are precursor states to active myeloma. It is therefore important to understand if, when, and how active myeloma might evolve and what monitoring and/or interventions are appropriate.

Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy.

Peripheral neuropathy (PN) is a complication of myeloma involving damage to the nerves of the peripheral nervous system that can be caused both by myeloma and by treatments for myeloma.

Pomalyst® (pomalidomide) in combination with Dexamethasone was approved by the U.S. Food and Drug Administration (FDA) on February 8, 2013 for relapsed and refractory myeloma.

Revlimid® (lenalidomide) has been approved by the FDA for use in myeloma.

Using Thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. Much has been learned about how Thalidomide works in the treatment of different diseases, and how its side effects can be treated.

This booklet will help you understand immune system basics. The immune system is extremely complex. It is made up of multiple mechanisms that work together to protect and defend the human body from external threats such as bacteria, viruses, and toxins, and from internal threats such as cancer.

This booklet will familiarize you with the way this combination therapy works, how it has been tested in clinical trials, the indication for which it is approved, how and when it is administered, its possible side effects and their management, and special precautions you need to take while taking VRd.

This booklet is focused on therapies given to patients with myeloma bone involvement. Bisphosphonate therapy is not treatment for myeloma, but it does help to prevent skeletal complications of myeloma. Monoclonal antibody therapy targets a protein which controls bone regeneration and remodeling.

As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress placed upon it.

This booklet covers the basics of FDA approved VELCADE® (bortezomib), including how it works, how it is administered, how is it used in clinical practice today, and side effects.

Xpovio, a new medication to treat myeloma, is a "nuclear export inhibitor," the first compound in this new drug class. Nuclear export inhibitors prevent cancer cells from expelling special genes in the cell nucleus called tumor suppressor proteins that help protect the cell from cancer.

This booklet outlines the tests that are used to diagnose and monitor myeloma, and to detect response and relapse. No single study is adequate to tell the whole story about a patient's status but, used together, test results give a more complete picture.